Conbercept ophthalmic injection

DRUG4 trials

Sponsors

Chengdu Kanghong Biotech Co., Ltd., First Affiliated Hospital of Zhejiang University

Conditions

Branch Retinal Vein OcclusionCentral Retinal Vein OcclusionMacular EdemaRetinal Vein OcclusionRetinoblastoma

Phase 2

A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma

Chengdu Kanghong Biotech Co., Ltd.Retinoblastoma

Start: 2021-07-05End: 2023-07-15Target: 92Updated: 2021-08-04

Phase 3

Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion

CompletedNCT03108352

Chengdu Kanghong Biotech Co., Ltd.Branch Retinal Vein Occlusion, Macular Edema

Start: 2016-04-13End: 2020-10-16Updated: 2022-07-15

Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion

CompletedNCT03223714

Chengdu Kanghong Biotech Co., Ltd.Central Retinal Vein Occlusion, Macular Edema

Start: 2016-05-24End: 2020-09-28Updated: 2022-07-13

Unknown Phase

A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut Microbiota

Not yet recruitingNCT07718503

First Affiliated Hospital of Zhejiang UniversityRetinal Vein Occlusion

Start: 2026-06-01End: 2028-12-31Target: 80Updated: 2026-07-22